DIAGNOSTIKA I LEChENIE GLYuKOKORTIKOIDNOGO OSTEOPOROZA


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

According to a large number of studies, the proportion of individuals anywhen taking oral glucocorticoids is 3 % at the age of 30 years, and increases to 5.2 % at the age of 80 years. It was found that the chronic administration of systemic glucocorticoids leads to osteoporotic fractures. Article is devoted to the most common and severe form of secondary osteoporosis, glucocorticoid-induced osteoporosis, developing as a result of prolonged use of glucocorticoids. New version of Russian clinical guidelines «Diagnosis, prevention and treatment of glucocorticoid-induced osteoporosis in men and women 18 years old and over», published in 2013 under the auspices of the Russian Association on Osteoporosis, Russian Respiratory Society and the Russia Association of Rheumatology is discussed. The recommendations for the management of patients taking oral glucocorticoids are presented.

Full Text

Restricted Access

About the authors

I. A Baranova

Email: iribaranova@yandex.ru

References

  1. Kanis J.A., Johansson H., Oden A., et al. A metaanalysis of prior corticosteroid use and fracture risk. J. Bone Miner Res. 2004;19:893-99.
  2. Dez-Prez A., Hooven F.H., Adachi J.D., et al. Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone. 2011;49:493-98.
  3. Van Staa T.P., Leufkens H.G., Abenhaim L., Zhang B., Cooper C. Use of oral corticosteroids and risk of fractures. J. Bone Miner. Res. 2000,15:933-1000.
  4. Van Staa T., Leufkens H.G.M., Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos. Int. 2002;13:777-87.
  5. Lekamwasam S., Adachi J.D., Agnusdei D., et al. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. 2012;23(9):2257-76.
  6. van Staa T.P., Leufkens H.G., Abenhaim L., et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatol. Phys. Med. 2000;39:1383-89.
  7. van Staa T.P., Leufkens H.G., Cooper C. Use of inhaled corticosteroids and risk of fractures. J. Bone Miner. Res. 2001;16:581-88.
  8. de Vries F., Bracke M., Leufkens H.G., et al. Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum. 2007;56:208-14.
  9. Лесняк О.М., Баранова И.А., Торопцова Н.В. Клинические рекомендации «Диагностика, профилактика и лечение глюкокортикоидного остеопороза у мужчин и женщин 18 лет и старше». Ярославль, 2013. 48 с.
  10. Reginster J.-Y., Minne H.W., Sorensen O.H., et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int. 2000;11:83-91.
  11. Wallach S., Cohen S., Reid D.M., Hughes R.A. et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif. Tissue Int. 2000;67:277-85.
  12. McClung M.R., Geusens P., Miller P.D., Zippel H., et al. Effects of risedronate on the risk of hip fracture in elderly women. N. Engl. J. Med. 2001;344:333-40.
  13. Johnell O., de Laet C., Johansson H., Melton L.J., et al. Oral corticosteroids increase fracture risk independently of BMD. Osteoporos. Int. 2002;13(suppl 1):S14.
  14. Leib E.S., Saag K.G., Adachi J.D., Geusens P.P., Binkley N., McCloskey E.V., Hans D.B., FRAX(®) Position Development Conference Members The impact of the use of glucocorticoids on the estimate by FRAX of the 10 year risk of fracture. J. Clin. Densitom. 2011;14:212-19.
  15. Kanis J.A., Johansson H., Oden A., et al. A metaanalysis of prior corticosteroid use and fracture risk. J. Bone Miner. Res. 2004;19:893-99.
  16. Kanis J.A., Johansson H., Oden A., McCloskey E. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos. Int. 2011;22:809-16.
  17. Rizzoli R., Boonen S., Brandi M.-L., et al. Vitamin D supplementation in elderly or postmenopausal women: a 2013 update of the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) Current Medical Res. Opinion. 2013;29(4):1-9.
  18. Adachi J.D., Saag K.G., Delmas P.D., et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum. 2001;44:202-11.
  19. de Nijs R.N., Jacobs J.W., Lems W.F., et al, Investigators STOP Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N. Engl. J. Med. 2006;355:675-84.
  20. Saag K.G., Emkey R., Schnitzer T.J., et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N. Engl. J. Med. 1998;339:292-99.
  21. Stoch S.A., Saag K.G., Greenwald M., Sebba A.I., et al. Once-weekly oral alendronate 70mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial. J Rheumatol 2009;36:1705-14.
  22. Yilmaz L., Ozpran K., Gndz O.H., et al. Alendronate in rheumatoid arthritis patients treated with methotrexate and glucocorticoids. Rheumatol Int 2001; 20:65-9.
  23. Cohen S., Levy R.M., Keller M., et al. Risedronate therapy prevents corticosteroidinduced bone loss: a twelve month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 1999;42:2309-18.
  24. Eastell R., Devogelaer J.-P., Peel N.F.A., et al. Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. Osteoporos. Int. 2000;11:331-37.
  25. Reid D.M., Adami S., Devogelaer J.P., Chines A.A. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif. Tissue Int. 2001;69:242-47.
  26. Reid D.M., Hughes R.A., Laan R.F., et al. Efficacy and safety of daily risedronate in the treatment of corticosteroidinduced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J. Bone Miner. Res. 2000; 15:1006-13.
  27. Wallach S., Cohen S., Reid D.M., et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif. Tissue Int. 2000;67:277-85.
  28. Reid D.M., Devogelaer J.P., Saag K., et al, HORIZON investigators Zoledronic acid and risedronate in the prevention and treatment of glucocorticoidinduced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2009;373:1253-63.
  29. de Nijs R.N., Jacobs J.W., Lems W.F, et al, Investigators STOP Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N. Engl. J. Med. 2006;355:675-84.
  30. de Nijs R.N., Jacobs J.W., Algra A., Lems W.F., Bijlsma J.W. Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with metaanalysis of randomized controlled trials including organ transplantation studies. Osteoporos. Int. 2004;15(8):589-602.
  31. Stoch S.A., Saag K.G., Greenwald M., et al. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial. J. Rheumatol. 2009;36(8):1705-14.
  32. http://www.ema.europa.eu/docs/en_GB/ document_library/Referrals_document/ Calcitonin_31/WC500130149.pdf

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies